GB-13
Glioblastoma (GBM) and Diffuse Midline Glioma (DMG)
Pre-clinicalActive
Key Facts
Indication
Glioblastoma (GBM) and Diffuse Midline Glioma (DMG)
Phase
Pre-clinical
Status
Active
Company
About Targepeutics
Targepeutics is a biotech startup advancing GB-13, a novel targeted immunotoxin, for uniformly fatal brain cancers with dismal survival rates and no new treatments in over 20 years. The company has secured FDA Orphan Drug Designation for GB-13 for GBM and DMG, validating the unmet need and providing regulatory benefits. Led by a small, experienced team with backgrounds in drug development and business, the company is preparing to initiate clinical trials while leveraging non-dilutive grant funding like SBIR awards. Its mission is driven by a personal connection to the disease and a commitment to integrating a new therapeutic into the standard of care.
View full company profile